JBM  Vol.3 No.8 , August 2015
The Current and Future Role of Drugs and Probiotics in the Management of Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) and other auto-inflammatory disorders are conditions caused by chronic and persistent intestinal inflammation, which is mainly represented by Ulcerative Colitis (UC) or Crohn’s Disease (CD), both of which typically arise as chronic inflammation of the gastrointestinal mucosa. Doctor’s main focus for treating IBD is the decrease on inflammation processes when the disease is active and promotes the maintenance of inflammation at normal levels. However, to deal with these two parameters is not easy, because the drugs usually used are related to several side effects and they are not totally effective to reduce inflammation and to keep the remission. Authors agree that the therapy approach should include drugs, dietary intervention and use of alternative substances as probiotics. The standard treatment approach for patients with CD and UC is traditionally done with the use of anti-inflammatory agents, like corticosteroids, mesalamine, immunomodulators such as azathioprine and methotrexate, and biologic agents such as infliximab and others. Probiotics are known as viable micro-organisms (or live microorganisms or live microbial dietary supplements) that may promote beneficial physiologic or therapeutic properties when used correctly. The interest in the role of these substances in improving human health is the reason of several researches. They may be used to help the immune system, to control gastro-intestinal infections and to prevent several diseases. Prebiotics, symbiotics, and probiotics may be helpful as adjuvants in the treatment of IBD. Probiotics are normally well-tolerated and are associated with few side effects which are undoubtedly important in the treatment of any disease.

Cite this paper
de Souza, M. , Barbalho, S. , Goulart, R. and de Carvalho, A. (2015) The Current and Future Role of Drugs and Probiotics in the Management of Inflammatory Bowel Disease. Journal of Biosciences and Medicines, 3, 76-85. doi: 10.4236/jbm.2015.38008.
[1]   Biasi, F., Leonarduzzi, G., Oteiza, P.I. and Poli, G. (2013) Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets. Antioxidants & Redox Signaling, 19, 1711-1747.

[2]   Steinmeyer, S., Lee, K., Jayaraman, A. and Alaniz, R.C. (2015) Microbiota Metabolite Regulation of Host Immune Homeostasis: A Mechanistic Missing Link. Current Allergy and Asthma Reports, 15, 524.

[3]   Okamoto, R. and Watanabe, M. (2015) Role of Epithelial Cells in the Pathogenesis and Treatment of Inflammatory, Bowel Disease. Journal of Gastroenterology. [Epub Ahead of Print]

[4]   Biasi, F., Deiana, M., Guina T., Gamba, P., Leonarduzzi, G. And Poli, G. (2014) Wine Consumption and Intestinal Redox Homeostasis. Redox Biology, 18, 795-802.

[5]   Wan, Y.C., Li, T., Han, Y.D., Zhang, H.Y., Lin, H. and Zhang, B. (2015) Effect of Pregnane Xenobiotic Receptor Activation on Inflammatory Bowel Disease Treated with Rifaximin. Journal of Biological Regulators and Homeostatic Agents, 29, 401-410.

[6]   LeBlanc, A.M., Del Carmen, S., Chatel, J.M., Miyoshi, A., Azevedo, V., Langella, P., Bermúdez-Humarán, L.G. and LeBlanc, J.G. (2015) Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. Gastroenterology Research and Practice, Article ID: 146972.

[7]   Moller, F.T., Andersen, V., Wohlfahrt, J. and Jess, T. (2015) Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011. The American Journal of Gastroenterology, 110, 564-571.

[8]   Zhang, Y.Z. and Li, Y.Y. (2014) Inflammatory Bowel Disease: Pathogenesis. World Journal of Gastroenterology, 20, 91-99.

[9]   Basso, P.J., Fonseca, M.T., Bonfá, G., et al. (2014) Association among Genetic Predisposition, Gut Microbiota, and Host Immune Response in the Etiopathogenesis of Inflammatory Bowel Disease. Brazilian Journal of Medical and Biological Research, 47, 727-737.

[10]   Tabbaa, M., Golubic, M., Roizen, M.F. and Bernstein, A.M. (2013) Docosahexaenoic Acid, Inflammation, and Bacterial Dysbiosis in Relation to Periodontal Disease, Inflammatory Bowel Disease, and the Metabolic Syndrome. Nutrients, 5, 3299-3310.

[11]   Brandse, J.F., Vos, L.M., Jansen, J., Schakel, T., Ponsioen, C.I., van den Brink, G.R., D’Haens, G.R. and Löwenberg, M. (2015) Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. Journal of Crohn’s and Colitis. [Epub ahead of print]

[12]   Cheifetz, A.S. (2013) Management of Active Crohn Disease. JAMA, 309, 2150-2158.

[13]   Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W. and Kaplan, G.G. (2012) Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology, 142, 46-54.

[14]   Nadorp, B. and Soreq, H. (2015) Gut Feeling: MicroRNA Discriminators of the Intestinal TLR9-Cholinergic Links. International Immunopharmacology. [Epub ahead of print]

[15]   Serhan, C.N. and Savill, J. (2005) Resolution of Inflammation: The Beginning Programs the End. Nature Immunology, 6, 1191-1197.

[16]   De Cruz, P., Prideaux, L., Wagner, J., Ng, S.C., McSweeney, C., Kirkwood, C., et al. (2012) Characterization of the Gastrointestinal Microbiota in Health and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 18, 372-390.

[17]   Medzhitov, R. (2010) Inflammation 2010: New Adventures of an Old Flame. Cell, 140, 771-776.

[18]   Nasef, N.A., Mehta, S., Powell, P., Marlow, G., Wileman, T. and Ferguson, L.R. (2015) Extracts of Feijoa Inhibit Toll-Like Receptor 2 Signaling and Activate Autophagy Implicating a Role in Dietary Control of IBD. PLoS ONE, 10, e0130910.

[19]   Silverberg, M.S., Satsangi, J., Ahmad, T., Arnott, I.D., Bernstein, C.N., Brant, S.R., Caprilli, R., Colombel, J.F., Gasche, C. and Geboes, K. (2005) Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology, 19, 5A-36A.

[20]   Shores, D.R., Binion, D.G., Freeman, B.A. and Baker, P.R. (2011) New Insights into the Role of Fatty Acids in the Pathogenesis and Resolution of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 17, 2192-2204.

[21]   Pavlov, V.A. and Tracey, K.J. (2012) Thevagus Nerve and the Inflammatory Reflex-Linking Immunity and Metabolism. Nature Reviews Endocrinology, 8, 743-754.

[22]   Krieg, A.M. and Vollmer, J. (2007) Toll-Like Receptors 7, 8, and 9: Linking Innate Immunity to Autoimmunity. Immunological Reviews, 220, 251-269.

[23]   Bonizzi, G. and Karin, M. (2004) The Two NF-κB Activation Pathways and Their Role in Innate and Adaptive Immunity. Trends in Immunology, 25, 280-288.

[24]   Paraskevi, A., Theodoropoulos, G., Papaconstantinou, I., Mantzaris, G., Nikiteas, N. and Gazouli, M. (2012) Circulating MicroRNA in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 6, 900-904.

[25]   Tas, S.W., Vervoordeldonk, M.J., Hajji, N., Schuitemaker, J.H., van der Sluijs, K.F. and May, M.J. (2007) Noncanonical NF-κB Signaling in Dendritic Cells Is Required for Indoleamine 2,3-Dioxygenase (IDO) Induction and Immune Regulation. Blood, 110, 1540-1549.

[26]   Sailaja, B.S., Cohen-Carmon, D., Zimmerman, G., Soreq, H. and Meshorer, E. (2012) Stress-Induced Epigenetic Transcriptional Memory of Acetylcholinesterase by HDAC4. Proceedings of the National Academy of Sciences of the United States of America, 109, E3687-E3695.

[27]   Zimmerman, G., Shaltiel, G., Barbash, B., Cohen, J., Gasho, C.J. and Shenhar-Tsarfaty, S. (2012) Post-Traumatic Anxiety Associates with Failure of the Innate Immune Receptor TLR9 to Evade the Pro-Inflammatory NFκB Pathway. Translational Psychiatry, 2, e78.

[28]   Netjes, J.E. and Rijken, M. (2013) Labor Participation among Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 19, 81-91.

[29]   Devlen, J., Beusterien, K., Yen, L., Ahmed, A., Cheifetz, A.S. and Moss, A.C. (2014) Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis. J Manag Care Spec Pharm, 20, 309-314.

[30]   Bielefeldtand, K., Davis, B. and Binion, D.G. (2009) Pain and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 15, 778-788.

[31]   Aghazadeh, R., Zali, M.R., Bahari, A., Amin, K., Ghahghaie, F. and Firouzi, F. (2005) Inflammatory Bowel Disease in Iran: A Review of 457 Cases. Journal of Gastroenterology and Hepatology, 20, 1691-1695.

[32]   Lix, L.M., Graff, L.A., Walker, J.R., Clara, I., Rawsthorne, P., Rogala, L., Miller, N., Ediger, J., Pretorius, T. and Bernstein, C. (2008) Longitudinal Study of Quality of Life and Psychological Functioning for Active, Fluctuating, and Inactive Disease Patterns in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 14, 1575-1584.

[33]   Kappelman, M.D., Rifas-Shiman, S.L., Kleinman, K., Ollendorf, D., Bousvaros, A., Grand, R.J. and Finkelstein, J.A. (2007) The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States. Clinical Gastroenterology and Hepatology, 5, 1424-1429. http://dx.doi.org/10.1016/j.cgh.2007.07.012

[34]   Burisch, J., Jess, T., Martinato, M. and Lakatos, P. (2013) The Burden of Inflammatory Bowel Disease in Europe, on Behalf of ECCO-EpiCom. Journal of Crohn’s and Colitis, 7, 322-337.

[35]   Matricon, J. (2010) Immunopathogenèse des maladies inflammatoireschroniques de l’intestin. M/S n° 4, vol. 26.

[36]   Lorén, V., Cabré, E., Ojanguren, I., Domènech, E., Pedrosa, E., García-Jaraquemada, A., et al. (2015) Interleukin-10 Enhances the Intestinal Epithelial Barrier in the Presence of Corticosteroids through p38 MAPK Activity in Caco-2 Monolayers: A Possible Mechanism for Steroid Responsiveness in Ulcerative Colitis. PLoS ONE, 10, e0130921.

[37]   Longui, C.A. (2007) Glucocorticoid Therapy: Minimizing Side Effects. Jornal de Pediatria, 83, S163-S171.

[38]   Brunton, L.L., Chabner, B.A. and Knollmann, B.C. (2012) Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition, AMGH Editora, Porto Alegre.

[39]   Moss, A.C. and Peppercorn, M.A. (2007) The Risks and the Benefits of Mesalazine as a Treatment for Ulcerative Colitis. Expert Opinion on Drug Safety, 6, 99-107.

[40]   Feagan, B.G., Chande, N. and MacDonald, J.K. (2009) Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 19, 2031-2040.

[41]   Kawashima, K., Ishihara, S., Yuki, T., Onishi, K., Kushiyama, Y., Fujishiro, H., et al. (2014) Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration. BioMed Research International, 2014, Article ID: 342751.

[42]   Riley, S.A., Tavares, I.A., Bennett, A. and Mani, V. (1988) Delayed-Release Mesalazine (5-Aminosalicylic Acid): Coat Dissolution and Excretion in Ileostomy Subjects. British Journal of Clinical Pharmacology, 26, 173-177.

[43]   Fernandez-Becker, N.Q. and Moss, A.C. (2008) Improving Delivery of Aminosalicylates in Ulcerative Colitis: Effect on Patient Outcomes. Drugs, 68, 1089-1103.

[44]   D’Incà, R., Paccagnella, M., Cardin, R., Pathak, S., Baldo, V., Giron, M.C. and Sturniolo, G.C. (2013) 5-ASA Colonic Mucosal Concentrations Resulting from Different Pharmaceutical Formulations in Ulcerative Colitis. World Journal of Gastroenterology, 19, 5665-5670.

[45]   Thomas, C.W., Myhre, G.M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D.J., Lipsky, J.J., Sandborn, W.J. and Egan, L.J. (2005) Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines. Journal of Pharmacology and Experimental Therapeutics, 312, 537-545.

[46]   Engelhardt, B. and Briskin, M.J. (2005) Therapeutic Targeting of α4-Integrins in Chronic Inflammatory Diseases: Tipping the Scales of Risk towards Benefit? European Journal of Immunology, 35, 2268-2273.

[47]   Swaminath, A., Taunk, R. and Lawlor, G. (2014) Use of Methotrexate in Inflammatory Bowel Disease in 2014: A User’s Guide. World Journal of Gastrointestinal Pharmacology and Therapeutics, 5, 113-121.

[48]   Wahed, M., Louis-Auguste, J.R., Baxter, L.M., Limdi, J.K., McCartney, S.A., Lindsay, J.O. and Bloom, S.L. (2009) Efficacy of Methotrexate in Crohn’s Disease and Ulcerative Colitis Patients Unresponsive or Intolerant to Azathioprine/Mercaptopurine. Alimentary Pharmacology & Therapeutics, 30, 614-620.

[49]   Absah, I. and Faubion, W.A. (2012) Concomitant Therapy with Methotrexate and Anti-TNF-α in Pediatric Patients with Refractory Crohn’s Colitis: A Case Series. Inflammatory Bowel Diseases, 18, 1488-1492.

[50]   Ko, J.K. and Auyeung, K.K. (2014) Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy. Current Pharmaceutical Design, 20, 1082-1096.

[51]   Löwenberg, M. and D’Haens, G. (2015) Next-Generation Therapeutics for IBD. Current Gastroenterology Reports, 17, 21.

[52]   Xu, Z., Davis, H.M. and Zhou, H. (2015) Clinical Impact of Concomitant Immunomodulators on Biologic Therapy: Pharmacokinetics, Immunogenicity, Efficacy and Safety. Journal of Clinical Pharma, 55, S60-S74.

[53]   Actis, G.C., Pellicano, R. and Rosina, F. (2015) Inflammatory Bowel Disease: Traditional Knowledge Holds the Seeds for the Future. World Journal of Gastrointestinal Pharmacology and Therapeutics, 6, 10-16.

[54]   Gungor, O.E., Kirzioglu, Z. and Kivanc, M. (2015) Probiotics: Can They Be Used to Improve Oral Health? Beneficial Microbes. [Epub ahead of print]

[55]   Fujimori, S. (2015) What Are the Effects of Proton Pump Inhibitors on the Small Intestine? World Journal of Gastroenterology, 21, 6817-6819.

[56]   Petrof, E.O. and Khoruts, A. (2014) From Stool Transplants to Next-Generation Microbiota Therapeutics. Gastroenterology, 146, 1573-1582.

[57]   Khoruts, A., Dicksved, J., Jansson, J.K. and Sadowsky, M.J. (2010) Changes in the Composition of the Human Fecal Microbiome after Bacteriotherapy for Recurrent Clostridium Difficile-Associated Diarrhea. Journal of Clinical Gastroenterology, 44, 354-360.

[58]   Ng, S.C., Hart, A.L., Kamm, M.A., Stagg, A.J. and Knight, S.C. (2009) Mechanisms of Action of Probiotics: Recent Advances. Inflammatory Bowel Diseases, 15, 300-310.

[59]   Caballero-Franco, C.K., Simone, K.C.D. and Chadee, K. (2007) The VSL#3 Probiotic Formula Induces Mucin Gene Expression and Secretion in Colonic Epithelial Cells. The American Journal of Physiology—Gastrointestinal and Liver Physiology, 292, G315-G322.

[60]   Kruidenier, L. and Verspaget, H.W. (2002) Review Article: Oxidative Stress as a Pathogenic Factor in Inflammatory Bowel Disease—Radicals or Ridiculous? Alimentary Pharmacology and Therapeutics, 16, 1997-2015.

[61]   Grompone, G.P. and Llopis, S.M. (2012) Anti-Inflammatory Lactobacillus rhamnosus CNCM I-3690 Strain Protects against Oxidative Stress and Increases Lifespan in Caenorhabditis elegans. PLoS ONE, 7, e52493.

[62]   Zagato, E., Mileti, E. and Massimiliano, L. (2014) Lactobacillus Paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells in Vitro and Protective Effects against Colitis and an Enteric Pathogen in Vivo. PLoS ONE, 9, e87615. http://dx.doi.org/10.1371/journal.pone.0087615

[63]   Kaci, G., Goudercourt, D. and Dennin, V. (2014) Anti-Inflammatory Properties of Streptococcus salivarius, a Commensal Bacterium of the Oral Cavity and Digestive Tract. Applied and Environmental Microbiology, 80, 928-934.

[64]   Duary, R.K., Bhausaheb, M.A., Batish, V.K. and Grover, S. (2012) Anti-Inflammatory and Immunomodulatory Efficacy of Indigenous Probiotic Lactobacillus plantarum Lp91 in Colitis Mouse Model. Molecular Biology Reports, 39, 4765-4775.

[65]   Fernandez, E.M., Valenti, V. and Rocke, C. (2011) Anti-Inflammatory Capacity of Selected Lactobacilli in Experimental Colitis Is Driven by NOD2-Mediated Recognition of a Specific Peptidoglycan-Derived Muropeptide. Gut, 60, 1050-1059.

[66]   Chaves, S., Perdigon, G. and LeBlanc, A.M. (2011) Yoghurt Consumption Regulates the Immune Cells Implicated in Acute Intestinal Inflammation and Prevents the Recurrence of the Inflammatory Process in a Mouse Model. Journal of Food Protection, 74, 801-811.

[67]   Rea, M.C., Clayton, E. and O’Connor, P.M. (2007) Antimicrobial Activity of Lacticin 3147 against Clinical Clostridium Difficile Strains. Journal of Medical Microbiology, 56, 940-946.

[68]   O’Mahony, L., Feeney, M. and O’Halloran, S. (2001) Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice. Alimentary Pharmacology and Therapeutics, 15, 1219-1225.

[69]   Hill, C., Guarner, F. and Reid, G. (2014) Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic. Nature Reviews Gastroenterology & Hepatology, 11, 506-514.

[70]   Yoshimatsu, Y., Yamada, A., Furukawa, R., Sono, K., Osamura, A., Nakamura, K., Aoki, H., Tsuda, Y., Hosoe, N., Takada, N. and Suzuki, Y. (2015) Effectiveness of Probiotic Therapy for the Prevention of Relapse in Patients with Inactive Ulcerative Colitis. World Journal of Gastroenterology, 21, 5985-5994.

[71]   Cruchet, S., Furnes, R., Maruy, A., Hebel, E., Palacios, J., Medina, F., et al. (2015) The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American Experts. Paediatric Drugs, 17, 199-216.

[72]   Ghouri, Y.A., Richards, D.M., Rahimi, E.F., Krill, J.T., Jelinek, K.A. and DuPont, A.W. (2014) Systematic Review of Randomized Controlled Trials of Probiotics, Prebiotics, and Synbiotics in Inflammatory Bowel Disease. Clinical and Experimental Gastroenterology, 7, 473-487.

[73]   Sartor, R.B. (2008) Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology, 134, 577-594.

[74]   Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005) Diversity of the Human Intestinal Microbial Flora. Science, 308, 1635-1638.

[75]   Asakura, H., Suzuki, K. and Honma, T. (2007) Recent Advances in Basic and Clinical Aspects of Inflammatory Bowel Disease: Which Steps in the Mucosal Inflammation Should We Block for the Treatment of Inflammatory Bowel Disease? World Journal of Gastroenterology, 13, 2145-2149. http://dx.doi.org/10.3748/wjg.v13.i15.2145

[76]   Steer, T., Carpenter, H., Tuohy, K. and Gibson, G.R. (2000) Perspectives on the Role of the Human Gut Microbiota and Its Modulation by Pro- and Prebiotics. Nutrition Research Reviews, 13, 229-254.

[77]   Othman, M., Agüero, R. and Lin, H.C. (2008) Alterations in Intestinal Microbial Flora and Human Disease. Current Opinion in Gastroenterology, 24, 11-16.

[78]   Mai, V. and Draganov, P.V. (2009) Recent Advances and Remaining Gaps in Our Knowledge of Associations between Gut Microbiota and Human Health. World Journal of Gastroenterology, 15, 81-85. http://dx.doi.org/10.3748/wjg.15.81

[79]   Shadnoush, M., Hosseini, R.S., Khalilnezhad, A., Navai, L., Goudarzi, H. and Vaezjalali, M. (2015) Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-Blind, Placebo-Controlled Clinical Trial. The Korean Journal of Gastroenterology, 65, 215-221.

[80]   Gibson, G.R. and Roberfroid, M.B. (1995) Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. Journal of Nutrition, 125, 1401-1412.

[81]   O’Mahony, L., Feeney, M., O’Halloran, S., Murphy, L., Kiely, B., Fitzgibbon, J., et al. (2001) Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice. Alimentary Pharmacology and Therapeutics, 15, 1219-1225.

[82]   Guarino, A., Vecchio, A.L. and Canani, R.B. (2009) Probiotics as Prevention and Treatment for Diarrhea. Current Opinion in Gastroenterology, 25, 18-23.

[83]   Indriyani, S. (2012) Effects of Live versus Heat-Killed Probiotics on Acute Diarrhea in Young Children. Paediatrica Indonesiana, 52, 249-254.

[84]   Lutgendorff, F., Akkermans, L. and Soderholm, J. (2008) The Role of Microbiota and Probiotics in Stress-Induced Gastro-Intestinal Damage. Current Molecular Medicine, 282-298.

[85]   Gerritsen, J., Smidt, H., Rijkers, G.T. and de Vos, W.M. (2011) Intestinal Microbiota in Human Health and Disease: The Impact of Probiotics. Genes & Nutrition, 6, 209-240.

[86]   Scaldaferri, F., Gerardi, V., Lopetuso, L.R., Del Zompo, F., Mangiola, F., Boskoski, I., et al. (2013) Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, Article ID: 435268.

[87]   Bergstrand, L.O., Gustafsson, B.E., Holmstrom, B. and Norin, K.E. (1981) The Physiological Activity of Human Ileal Flora in Patients with Crohn’s Disease and Ulcerative Colitis Evaluated by Determination of Germfree Animal Characteristics. Actachirscand, 147, 707-709.

[88]   Van der Merve, J.P. and Mol, G.J.J. (1982) Levels of Trypsin and Alpha-Chymotrypsin in Feces from Patients with Crohn’s Disease. Digestion, 24, 1-4.

[89]   Midtvedt, T., Zabarovsky, E., Norin, E., Bark, J., Gizatullin, R., Kashuba, V., et al. (2013) Increase of Faecal Tryptic Activity Relates to Changes in the Intestinal Microbiome: Analysis of Crohn’s Disease with a Multidisciplinary Platform. PLoS ONE, 8, e66074.